Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sotac PharmaceuticalsNSE:SOTAC 53 ROC (Joel Greenblatt) % is 16.63% as of Mar. 2026, which is 30% above its 10-year median of 12.75. GuruFocus rates NSE:SOTAC with a GF Score™ of 53/100 and a GF Value™ of ₹141.52 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 983 Drug Manufacturers companies, Sotac Pharmaceuticals ranks better than 55.14% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Sotac Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 16.63%.
The historical rank and industry rank for Sotac Pharmaceuticals's ROC (Joel Greenblatt) % or its related term are showing as below:
NSE:SOTAC'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -6.12 Med: 12.75 Max: 27.08
Current: 13.96
During the past 7 years, Sotac Pharmaceuticals's highest ROC (Joel Greenblatt) % was 27.08%. The lowest was -6.12%. And the median was 12.75%.
NSE:SOTAC's ROC (Joel Greenblatt) % is ranked better than 55.14% of 983
companies
in the Drug Manufacturers industry
Industry Median: 11.44
vs NSE:SOTAC: 13.96
Sotac Pharmaceuticals's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Sotac Pharmaceuticals ROC (Joel Greenblatt) % Related Terms
Sotac Pharmaceuticals ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Sotac Pharmaceuticals's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:SOTAC vs ZTS: ROC (Joel Greenblatt) % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Sotac Pharmaceuticals's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sotac Pharmaceuticals ROC (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sotac Pharmaceuticals's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Sotac Pharmaceuticals's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is two times the semi-annual (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 16.63% mean?
Sotac Pharmaceuticals (NSE:SOTAC) has a ROC (Joel Greenblatt) % of 16.63% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Sotac Pharmaceuticals and its competitors. This is 30% above median its historical median of 12.75. According to the industry distribution chart, Sotac Pharmaceuticals ranks #441 out of 983 companies in the Drug Manufacturers industry, placing it in the top 44.9%.
Is Sotac Pharmaceuticals' ROC (Joel Greenblatt) % too high?
Sotac Pharmaceuticals' current ROC (Joel Greenblatt) % of 16.63% is 30% above median its 10-year median of 12.75. The Drug Manufacturers industry median ROC (Joel Greenblatt) % is 11.44. Sotac Pharmaceuticals' value of 16.63% is 45.4% above this industry median. Based on the distribution chart, Sotac Pharmaceuticals ranks #441 out of 983 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Sotac Pharmaceuticals has a GF Score™ of 53/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sotac Pharmaceuticals' ROC (Joel Greenblatt) % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Sotac Pharmaceuticals ranks #441 out of 983 companies for ROC (Joel Greenblatt) %. This puts Sotac Pharmaceuticals in the upper half of its industry. The industry median ROC (Joel Greenblatt) % is 11.44. Sotac Pharmaceuticals' value of 16.63% is 45.4% above this benchmark. While the company's 10-year median is 12.75 vs. the industry median of 11.44, Sotac Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Drug Manufacturers company?
The median ROC (Joel Greenblatt) % among Drug Manufacturers companies is 11.44, based on 983 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sotac Pharmaceuticals's current ROC (Joel Greenblatt) % of 16.63% is 45.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Sotac Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median ROC (Joel Greenblatt) % is 11.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sotac Pharmaceuticals's current ROC (Joel Greenblatt) % is 16.63%, which is 30% above median its own 10-year median of 12.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sotac Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Sotac Pharmaceuticals (NSE:SOTAC) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹141.52, compared to a current price of ₹91.95 — trading 35% below its estimated fair value. The current ROC (Joel Greenblatt) % is 16.63%, which is 30% above median its 10-year median of 12.75 and 45.4% above the Drug Manufacturers industry median of 11.44. Sotac Pharmaceuticals' overall GF Score™ is 53/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Sotac Pharmaceuticals (NSE:SOTAC), the current ROC (Joel Greenblatt) % is 16.63% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sotac Pharmaceuticals (NSE:SOTAC) Overvalued in 2026?
Based on GuruFocus' analysis, Sotac Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹91.95 is trading 35% below its estimated GF Value™ of ₹141.52.
GuruFocus considers Sotac Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for NSE:SOTAC:
ROC (Joel Greenblatt) %: 16.63% (30% above median its 10-year median of 12.75)
GF Value™: ₹141.52 vs. price of ₹91.95 (35% below fair value)
Industry Position: 45.4% above the Drug Manufacturers median (#441 of 983)
No single metric tells the full story. See the NSE:SOTAC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sotac Pharmaceuticals Ltd operates chiefly in pharmaceutical manufacturing, serving a broad range of therapeutic segments including anti-diabetic, anti-psychotic, vitamins and minerals, anti-cold, anti-allergic, derma products, antacids, anti-ulcerants, cardiac, analgesic, anti-bacterial, anti-fungal, and more. The company manufactures tablets, capsules, syrups, and external preparations under contract manufacturing and loan licensing agreements, for domestic and international markets. Its clients include notable pharmaceutical marketers such as Cadila Pharma and Viatris. Revenue is distributed between domestic pharmaceutical product sales and international exports, supporting scalable growth across geographies.
53GF Score
Get the complete analysis for NSE:SOTAC
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SOTAC has been successfully added to your 
